Skip to content

Disc Medicine IRON Return on equity

Return on equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
38.8%+7.3pp
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
24.2%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-17.1%-26.1pp
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-32.8%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-47.1%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-706%-1,302pp

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Calculated from Disc Medicine’s reported figures.

Based on trailing twelve months.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's return on equity?
Disc Medicine (IRON) reported return on equity of -35.8% in Q1 2026.
How has Disc Medicine's return on equity changed year-over-year?
Disc Medicine's return on equity decreased by 53.5% year-over-year, from -23.3% to -35.8%.
What is the long-term trend for Disc Medicine's return on equity?
Over 2 years (2023 to 2025), Disc Medicine's return on equity has grown at a 10.6% compound annual growth rate (CAGR), from -29.3% to -35.9%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.